Last reviewed · How we verify
Icovamenib HPMC — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Icovamenib HPMC (Icovamenib HPMC) — Biomea Fusion Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Icovamenib HPMC TARGET | Icovamenib HPMC | Biomea Fusion Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Icovamenib HPMC CI watch — RSS
- Icovamenib HPMC CI watch — Atom
- Icovamenib HPMC CI watch — JSON
- Icovamenib HPMC alone — RSS
Cite this brief
Drug Landscape (2026). Icovamenib HPMC — Competitive Intelligence Brief. https://druglandscape.com/ci/icovamenib-hpmc. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab